Abstract
In this issue of Blood, Burns and colleagues analyzed samples from 18 patients with melanoma, treated with T lymphocytes gene-modified to express a tumor-specific TCR. Results show persistence of transduced cells, but early shutdown of TCR gene expression. Transgene down-regulation was not caused by epigenetic silencing and could be reversed by T-cell activation.
| Original language | English |
|---|---|
| Pages (from-to) | 2855-2856 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 114 |
| Issue number | 14 |
| DOIs | |
| Publication status | Published - 2009 |
ASJC Scopus subject areas
- Hematology
- Biochemistry
- Cell Biology
- Immunology